Abbott reports strong 30-day outcomes in TECTONIC IVL study
The TECTONIC CAD IVL IDE Study enrolled 335 patients and met its primary safety endpoint with a 30-day target lesion failure rate of 0.3%. The study also achieved a primary effectiveness endpoint with procedural success in 97% of patients.
Primary source
Company press release (PR Newswire), November 1, 2026
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Machine-summarized from the source above; not independently reported. How we use automation